| Company
| Exchange
| Symbol
| Last price
|
| Quote change
| Market cap
|
|
|
Pharmasset, Inc.
| NASDAQ
|
VRUS
|
0.0000
|
|
|
|
|
|
Pharmasset, Inc. is a clinical-stage pharmaceutical company focused on
discovering, developing, and commercializing novel drugs to treat viral
infections.
| |
| |
|
|
Idenix Pharmaceuticals Inc
| NASDAQ
|
IDIX
|
4.31
|
|
+0.12
(2.86%)
| 577.36M
|
|
|
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in
the discovery and development of drugs for the treatment of human viral ...
| |
| |
|
|
Gilead Sciences, Inc.
| NASDAQ
|
GILD
|
55.81
|
|
+0.33
(0.59%)
| 85.13B
|
|
|
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company
that discovers, develops and commercializes medicines.
| |
| |
|
|
PHARMASSET INC DL-,001
| FRA
|
BW6
|
105.70
|
|
|
|
|
|
|
|
|
GILEAD SCIENCES DL-,001
| FRA
|
GIS
|
43.04
|
|
+0.04
(0.10%)
|
|
|
|
|
|
|
IDENIX PHARMACEUT.DL-,001
| FRA
|
NO9
|
3.18
|
|
+0.10
(3.11%)
|
|
|
|
|
|
|
GILEAD SCIENCES DL-,001
| ETR
|
GIS
|
43.15
|
|
-0.15
(-0.33%)
|
|
|
|
|
|
|
PerkinElmer, Inc.
| NYSE
|
PKI
|
31.73
|
|
-0.03
(-0.09%)
| 3.55B
|
|
|
PerkinElmer, Inc. is a provider of technology, services and solutions to the
diagnostics, research, environmental, industrial and laboratory services ...
| |
| |
|
|
Qiagen NV
| NASDAQ
|
QGEN
|
18.98
|
|
+0.05
(0.26%)
| 4.44B
|
|
|
Provides genetically oriented technlogy. The Company provides enabling
technologies and products for separating and purifying nucleic acids (DNA and
RNA).
| |
| |
|
|
Qiagen NV
| FRA
|
QIA
|
14.65
|
|
+0.18
(1.24%)
| 3.43B
|
|
|
Provides genetically oriented technlogy. The Company provides enabling
technologies and products for separating and purifying nucleic acids (DNA and
RNA).
| |
| |
|
|
Qiagen NV
| ETR
|
QIA
|
14.66
|
|
+0.16
(1.14%)
| 3.43B
|
|
|
Provides genetically oriented technlogy. The Company provides enabling
technologies and products for separating and purifying nucleic acids (DNA and
RNA).
| |
| |
|
|
PERKINELMER INC. DL 1
| FRA
|
PKN
|
24.31
|
|
-0.24
(-0.97%)
|
|
|
|
|
|
|
Bristol Myers Squibb Co.
| NYSE
|
BMY
|
47.40
|
|
+0.40
(0.85%)
| 77.86B
|
|
|
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development,
licensing, manufacturing, marketing, distribution and sale of biopharmaceutical
...
| |
| |
|
|
Helicos BioSciences Corp.
| OTCMKTS
|
HLCSQ
|
0.0035
|
|
0.0000
(0.00%)
| 304,615.00
|
|
|
Helicos Biosciences Corporation is a United States-based life science company.
The Company develops genetic technologies for the research, drug discovery ...
| |
| |
|
|
Marina Biotech, Inc.
| OTCMKTS
|
MRNA
|
0.255
|
|
-0.024
(-8.72%)
| 4.18M
|
|
|
Marina Biotech, Inc. is a biotechnology company focused on the discovery,
development and commercialization of nucleic acid-based therapies utilizing gene
...
| |
| |
|
|
Bristol Myers Squibb Co.
| NYSE
|
BMY-
|
566.10
|
|
0.00
(0.00%)
| 77.31B
|
|
|
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development,
licensing, manufacturing, marketing, distribution and sale of biopharmaceutical
...
| |
| |
|
|
Meridian Bioscience, Inc.
| NASDAQ
|
VIVO
|
21.89
|
|
+0.23
(1.06%)
| 906.60M
|
|
|
... polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (
qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by
...
| |
| |
|
|
Enzo Biochem, Inc.
| NYSE
|
ENZ
|
2.23
|
|
-0.01
(-0.45%)
| 87.81M
|
|
|
Enzo Biochem, Inc. (Enzo), is an integrated life sciences and biotechnology
company. Enzo has three segments: Enzo Clinical Labs, Enzo Life Sciences, ...
| |
| |
|
|
Enanta Pharmaceuticals Inc
| NASDAQ
|
ENTA
|
20.00
|
|
+0.14
(0.70%)
| 336.73M
|
|
|
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology
company. The Company uses its chemistry-driven approach and drug discovery ...
| |
| |
|
|
BRISTOL-MYERS SQUIBBDL-10
| FRA
|
BRM
|
35.94
|
|
+0.43
(1.22%)
|
|
|
|
|
|
